Navigation Links
CareFusion Reports First Quarter Fiscal 2012 Results
Date:11/7/2011

e table may not equal the per share amounts presented. CAREFUSION CORPORATIONADJUSTED FINANCIAL INFORMATION(UNAUDITED)Quarter Ended September 30, 2011Nonrecurring(in millions, except per share amounts)GAAP Items(1)Adjusted(2)Revenue(3)$

844

$

-

$

844Cost of Products Sold417-417Gross Margin427-427Selling, General and Administrative Expenses273(4)269Research and Development Expenses39-39Restructuring and Acquisition Integration Charges 7(7)-Operating Income10811119Interest Expense and Other, Net 25-25Income Before Income Tax831194Provision for Income Tax16218Net Income $

67

$

9

$

76Per Share Amounts:(4)Basic Earnings per Common Share$

0.30

$

0.04

$

0.34Diluted Earnings per Common Share$

0.30

$

0.04

$

0.33Weighted-Average Number of Common Shares Outstanding:Basic223.8223.8223.8Diluted 226.3226.3226.3Effective Tax Rate19.0%25.5%19.8%____________1Reflects nonrecurring charges primarily related to the spinoff and nonrecurring restructuring charges.  2Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.3Revenues increased $33 million or 4% for the quarter ended September 30, 2011 compared to 2010, on a constant currency basis, the increase is 3%.4Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented. CAREFUSION CORPORATIONADJUSTED FINANCIAL INFORMATION(UNAUDITED)Quarter Ended September 30, 2010DiscontinuedNonrecurring(in millions, except per share amounts)GAAP Operations(1)Items(2)Adjusted(3)Revenue$

811

$

-

$

-

$

811Cost of Products Sold398--398Gross Margin413--413Selling, General and Administrative Expenses272-(17)255Researc
'/>"/>

SOURCE CareFusion
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ERT Closes the Acquisition of the Research Services Division of CareFusion Corporation
2. Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011
3. InterMune Reports Third Quarter 2011 Financial Results and Business Highlights
4. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
5. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
6. Caliper Life Sciences Reports Third Quarter 2011 Results
7. Neurocrine Biosciences Reports Third Quarter 2011 Results
8. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
9. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
11. ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Rock Hill, SC (PRWEB) October 22, 2014 ... the expansion of its cardiovascular pharmacogenetics menu, which ... improved patient outcomes. With PCLS’s evidence-based results, ... individual needs and optimize their therapy, while minimizing ... , In the U.S., according to the FDA ...
(Date:10/22/2014)... ROCKVILLE, Md. , Oct. 22, 2014   ... company developing novel pathogen-specific therapies for serious infections and ... Office has issued a Notice of Allowance for a ... product in its C. difficile program, SYN-004. This ... to SYN-004 in the U.S. and adds to the ...
(Date:10/22/2014)... Oct. 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) ... million people worldwide are living with diabetes, with  that ... 2030.  The global market for diabetes treatments is approximately ... people worldwide died from pancreatic cancer.  Pancreatic cancer is ... cancer in the United States , ...
(Date:10/22/2014)... KONG , Oct. 22, 2014  aTyr Pharma ... that rare disease expert John C. McKew , ... McKew brings more than two decades of expertise in ... Institutes of Health, Wyeth Research and Genetics Institute, Inc. ... aTyr,s efforts to expand and translate its novel Physiocrine ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... EMERYVILLE, Calif., Dec. 2 Bionovo, Inc.,(Nasdaq: BNVI ), ... effective drugs in the areas of women,s health and,cancer, announced that ... of the Company at the 20th Annual Piper Jaffray Health,Care Conference ... will be held at,the New York Palace Hotel in New York ...
... Va., and SAN DIEGO, Dec. 2 The Patient,Advocate ... is,pleased to announce the launch of the Lymphedema CareLine ... toll-free patient/provider,hotline designed to provide information and assistance to ... for post-treatment side effects such as,lymphedema (swelling due to ...
... Corporation (Nasdaq: MATK ) announced that it intends to ... on December 11, 2008, at approximately 4:00 p.m. Eastern Time (ET). ... a conference call to discuss these results with investors. All ... visiting Martek,s web site at http://investors.martek.com . , ...
Cached Biology Technology:Bionovo to Present at the Piper Jaffray Healthcare Conference 2New Program Offers Breast Cancer Clinicians and Patients Support for Pre-Operative Clinical Assessment and Ongoing Surveillance of Lymphedema 2New Program Offers Breast Cancer Clinicians and Patients Support for Pre-Operative Clinical Assessment and Ongoing Surveillance of Lymphedema 3
(Date:10/22/2014)... Oct. 20, 2014 The Nano-Bio Manufacturing Consortium ... Force Research Laboratory (AFRL), has chosen a project proposed ... the University of Arizona College of Medicine – ... AzCIM project,s goal is to assess different sweat collection ... volumes of sweat under a variety of human-body conditions, ...
(Date:10/18/2014)... stress and stress-related psychiatric disorders are associated ... the molecular mechanisms underlying this relation are ... the development of targeted preventive strategies and ... diseases. This work is presented at the ... Now an international group of researchers from ...
(Date:10/17/2014)... in German . ... day in order to reproduce? And why are there two ... the latest issue of the research journal Molecular Human ... Steven Ramm from Bielefeld University Bielefeld has compiled this special ... for a female to copulate with several males in quick ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Researchers find why depression and aging linked to increased disease risk 2Sperm wars 2
... the Welsh national flower, which could offer hope for sufferers ... by Cardiff University's Manufacturing Engineering Centre (MEC). , Alzheimer's disease ... per cent of all cases of dementia. Dementia affects one ... person in five over the age of 80. , Certain ...
... step closer to a technique to easily detect a ... The findings, currently online in the Proceedings of the ... of DNA into cell cultures and observing whether they ... proteins. , The technique could enable doctors to ...
... DNA molecule that is copied almost as efficiently as ... online edition of the Proceedings of the National Academy ... genetic mutations-tiny mistakes that occur during DNA replication-arise. The ... a professor of chemistry at Stanford and co-author of ...
Cached Biology News:Scientists closer to new cancer detection method 2Scientists closer to new cancer detection method 3DNA size a crucial factor in genetic mutations, study finds 2DNA size a crucial factor in genetic mutations, study finds 3
Anti-Mouse IgM Heavy Chain:FITC, Clone LO-MM-9, Monoclonal Antibody...
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
PI/RNase Staining Buffer Solution , 100 ml Consult technical datasheet for details....
Biology Products: